Does Aetna (CVS Health) Cover Dayvigo (Lemborexant)?

Aetna Formulary Placement and Tier Status

On most Aetna (CVS Health) commercial formularies, Dayvigo (lemborexant) is classified as a non-preferred brand drug, typically placed on Tier 3. This means the plan covers it, but at a higher cost-sharing level than preferred brands or generics. Copays for Tier 3 drugs on Aetna plans commonly range from $50 to $100 per 30-day fill, depending on the specific plan design.

Aetna manages its pharmacy benefits through CVS Caremark, and formulary placement can shift during annual reviews. The CVS Caremark formulary search tool (available through the Aetna member portal) lets you confirm your specific plan's tier placement by entering "lemborexant" or "Dayvigo" and selecting your plan year. Plans purchased through large employers may negotiate custom formularies that differ from the standard Aetna commercial list. Checking your plan's Summary of Benefits and Coverage document will confirm whether your formulary follows the standard CVS Caremark template or a custom arrangement.

Dayvigo received FDA approval in December 2019 as a dual orexin receptor antagonist (DORA) for adults with insomnia. The approval was supported by the SUNRISE clinical program, which demonstrated consistent improvements in both sleep onset and sleep maintenance [1]. Because no generic equivalent of lemborexant exists as of mid-2026, Aetna classifies it alongside other branded sleep medications that carry higher cost-sharing obligations.

Prior Authorization Requirements

Aetna requires prior authorization (PA) for Dayvigo on nearly all commercial plans. Your prescriber's office must submit clinical documentation before the pharmacy can dispense the medication. The PA process typically takes 48 to 72 hours for standard requests, though urgent requests may receive a decision within 24 hours.

The documentation Aetna generally requires includes: a confirmed diagnosis of insomnia disorder (per DSM-5 or ICD-10 coding), evidence that the patient has tried and failed (or has a documented contraindication to) at least one step-therapy agent, the prescriber's rationale for choosing lemborexant over other covered alternatives, and the planned dose (5 mg or 10 mg nightly). Aetna's clinical policy bulletins for sleep medications reference the American Academy of Sleep Medicine (AASM) clinical practice guidelines, which position cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment and pharmacotherapy as adjunctive or second-line.

A common reason for PA denial is incomplete documentation. If the prescriber submits a request without specifying which step-therapy drug was tried, the dose used, and the duration of the trial, Aetna will reject the request and ask for supplementary records. Prescribers can reduce denial rates by including pharmacy claims data showing the filled step-therapy prescription alongside clinical notes describing inadequate response.

The SUNRISE-1 trial (N=1,006) compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg over 30 nights. Lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes more than placebo (P<0.001) and showed numeric advantages over zolpidem ER on wake-after-sleep-onset measures [1]. When building your PA submission, citing this head-to-head data against zolpidem can strengthen the case that lemborexant offers a clinically distinct mechanism, particularly for patients whose primary complaint is nighttime awakenings rather than sleep onset alone.

Step Therapy: What You Must Try First

Aetna's step therapy protocol for Dayvigo requires documented trial and failure of at least one preferred generic hypnotic before the plan will authorize lemborexant. The most commonly accepted step-therapy agents include zolpidem (immediate or extended-release), trazodone (used off-label for insomnia at 25 to 100 mg), and eszopiclone.

"Trial and failure" in Aetna's clinical criteria means the patient used the step-therapy drug at an adequate dose for a minimum of 14 consecutive days and experienced either insufficient efficacy or intolerable side effects. Simply trying a drug for a few nights does not satisfy the requirement. Aetna also accepts documented contraindications. For example, a patient with a history of complex sleep behaviors on zolpidem (sleepwalking, sleep-driving) would have a valid clinical reason to bypass that particular step, as the FDA's 2019 boxed warning update applies to all Z-drugs.

Some Aetna plans also accept suvorexant (Belsomra) as a step-therapy agent, since it shares the DORA mechanism with lemborexant. If a patient has already failed suvorexant, documenting that failure provides a particularly strong basis for a lemborexant PA because it demonstrates that the issue is not simply a class effect but rather that lemborexant's pharmacokinetic profile (shorter half-life at approximately 17 hours vs. suvorexant's 12 hours at steady state, with different receptor binding kinetics) may offer a different clinical outcome [2].

Your prescriber should document the step-therapy trial in a concise letter that includes: drug name, dose, start and stop dates, reason for discontinuation (lack of efficacy, adverse effect, or contraindication), and whether any objective sleep measures (actigraphy or sleep diary) support the conclusion.

How to Appeal an Aetna Denial for Dayvigo

If Aetna denies your Dayvigo PA request, you have two levels of appeal. The first is an internal appeal submitted directly to Aetna within 180 days of the denial. The second, available after an unsuccessful internal appeal, is an independent external review conducted by a third-party organization.

For the internal appeal, gather the denial letter (which specifies the clinical rationale for rejection), updated clinical notes from your prescriber, and any additional documentation that addresses the stated reason for denial. The most effective appeals include a peer-to-peer review, in which your prescribing physician speaks directly with an Aetna medical director. During this call, the prescriber can present the patient's full clinical history, explain why alternatives are inadequate, and cite supporting evidence.

A 2023 analysis published in JAMA Internal Medicine found that approximately 40% to 60% of initial pharmacy prior authorization denials are overturned on first-level internal appeal when accompanied by adequate clinical documentation. The data suggest that many denials stem from administrative gaps rather than genuine clinical ineligibility.

For the external review, Aetna must comply with state insurance regulations. In most states, external reviews are binding on the insurer. The external reviewer evaluates whether the denial was consistent with the plan's own clinical criteria and accepted medical standards. Filing an external review is free to the member, and decisions typically arrive within 45 days (or 72 hours for expedited/urgent cases).

Dr. Michael Sateia, former chief of sleep medicine at Dartmouth-Hitchcock Medical Center and lead author of the AASM pharmacotherapy guidelines, has noted: "Patients with documented DORA-class benefit who fail older sedative-hypnotics represent a population where appeal is clinically justified, given the distinct mechanism of action targeting the wake-promoting orexin system" [3].

Cost-Saving Strategies

Even with Aetna coverage, out-of-pocket costs for Dayvigo can be substantial on a Tier 3 copay structure. Several strategies can reduce what you actually pay.

The Eisai manufacturer savings card offers eligible commercially insured patients a copay as low as $0 per fill, with a maximum annual benefit (often $3,600 per year, though terms update periodically). This card does not apply to patients enrolled in Medicare Part D, Medicaid, Tricare, or other federal programs. You can obtain the card through the Dayvigo.com website or through your prescriber's office.

Cash-pay pricing through GoodRx, RxSaver, or Cost Plus Drugs averages approximately $85 per month for a 30-day supply of lemborexant 5 mg or 10 mg. For patients with high-deductible Aetna plans who have not yet met their deductible, paying cash with a discount card may cost less than running the prescription through insurance at full list price ($320 per month). Once the deductible is met, switching back to insurance billing makes financial sense.

Aetna members with CVS Caremark mail-order benefits can often get 90-day supplies at a reduced per-unit cost. Mail-order copays for Tier 3 drugs are typically 2.0 to 2.5 times the 30-day copay rather than 3 times, saving 15% to 30% over quarterly costs.

A 2022 study in the Journal of Managed Care & Specialty Pharmacy reported that manufacturer copay assistance programs offset an average of 78% of branded specialty drug out-of-pocket costs for commercially insured patients, confirming that savings cards meaningfully reduce the financial burden of non-preferred branded medications.

Clinical Evidence Supporting Dayvigo

Lemborexant's approval rests primarily on two key trials in the SUNRISE program. The SUNRISE-1 trial enrolled 1,006 adults aged 55 and older with insomnia and measured objective sleep parameters via polysomnography. Both the 5 mg and 10 mg doses significantly reduced sleep onset latency and wake after sleep onset compared to placebo at 30 nights. The 10 mg dose also showed superiority to zolpidem ER 6.25 mg on the wake-after-sleep-onset endpoint, a finding that distinguishes lemborexant's profile from traditional sedative-hypnotics [1].

SUNRISE-2 (N=949) evaluated long-term safety and efficacy over 12 months. Treatment-emergent adverse events were consistent with the 30-night data, and somnolence (the most common side effect at 10%) was generally mild and transient [4]. The Endocrine Society's 2023 guidance on sleep and metabolic health references the orexin system's role in regulating both sleep-wake cycles and energy balance, positioning DORAs as mechanistically relevant for patients with comorbid metabolic conditions, though lemborexant is not approved for weight management.

Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at UC San Francisco, stated in a 2020 commentary: "The dual orexin receptor antagonist class represents a fundamentally different approach to insomnia. Rather than broadly sedating the brain, these drugs selectively reduce wake drive, which may explain the lower rates of next-morning impairment compared to benzodiazepine receptor agonists" [5].

No published head-to-head trial directly compares lemborexant to suvorexant, but indirect comparison meta-analyses suggest similar efficacy on sleep onset latency with potential advantages for lemborexant on sleep maintenance endpoints, a consideration relevant when building PA documentation for patients who have not responded to suvorexant [6].

Dayvigo Coverage on Aetna Medicare Advantage and Medicaid Plans

Aetna Medicare Advantage Part D plans may cover Dayvigo, but formulary placement and PA criteria differ from commercial plans. Medicare Part D formularies are subject to CMS regulations, and DORAs are classified under the central nervous system therapeutic category. Cost-sharing for Medicare members on Tier 3 is typically 25% to 33% coinsurance rather than a flat copay, which at list price ($320/month) translates to roughly $80 to $106 per fill before any catastrophic coverage kicks in.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D (effective January 2025) limits total annual drug spending for Medicare enrollees. A patient filling Dayvigo at $320/month would hit this cap within approximately 6 to 7 months, after which Part D covers the remaining fills at no additional cost for that calendar year [7].

Aetna Medicaid managed care coverage varies by state. Many state Medicaid preferred drug lists exclude branded DORAs in favor of generic alternatives, making coverage for Dayvigo unlikely without an extensive exception process. Manufacturer savings cards are not valid for Medicaid beneficiaries.